🇺🇸

US SEC Filing Intelligence

· daily

US Merger & Acquisition SEC Filings — March 24, 2026

The 9 filings reveal robust M&A and takeover activity dominated by SPACs (6/9 filings) facing mixed fortunes, including PIPE financings, non-redemption support, administrative deals, but also delisting risks, alongside operating company divestitures and acquisitions showing pro forma financial improvements. Key period-over-period trends include revenue declines in divested units (Cardlytics: 2025 revenue down 9% pro forma to $212.3M) but narrower net losses (79% improvement in 2024 to $(40.4M)), EBITDA margin expansion via accretive deals (LSI: combined 11% from 9.7%), and secured future cash flows (Playboy: $122M contracted through 2033). Critical developments like LSI's $325M acquisition and Playboy's $15M JV sale signal strategic portfolio optimization, while SPAC challenges (Oak Woods delisting March 25, 2026) highlight deadline pressures post-36 months. Portfolio-level patterns show 3/9 with positive pro forma metrics (narrower losses, higher EBITDA), contrasting SPAC neutral/negative sentiment; sector themes point to industrials/licensing M&A strength amid SPAC fatigue. Implications favor monitoring post-deal integrations and SPAC closings for near-term catalysts, with asset-light shifts boosting returns.

9 high priority 9 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 24, 2026

Overnight SEC filings from March 23-24, 2026, reveal mixed financial momentum across US equities, with standout revenue accelerations in infrastructure (Smith-Midland Q4 +25% YoY to $22-24M, FY +18% to $92-94M) and solar (FTC Solar FY2025 +110.5% to $99.7M), offset by persistent net losses and operational pressures in 7/15 key 10-K/20-F reporters (e.g., Vertical Aerospace op loss +108% to £127M despite net profit swing). REITs and private credit funds shine with CareTrust REIT Normalized FFO +17% YoY to $1.76/share and record $1.764B cap deployment, Audax portfolio +46% to $949.8M, and Golub $10.2B portfolio at 1.33x leverage. Galaxy entities' 13F series disclose massive crypto/mining concentrations (e.g., $137.8B portfolio Q3 2025 with Core Scientific $19B), signaling bullish conviction amid volatility. Debt restructurings/waivers proliferate (FTC Solar $10M repayments, Inotiv liquidity waiver, Southland $110M assignment), raising liquidity flags in 5 firms, while capital returns persist via buybacks (News Corp $1B program, Flowco 780K shares) and dividends (Braemar prefs, Golub $0.1875/share). M&A speculation emerges (Estee Lauder/Puig talks), and proxies indicate governance stability (QXO/Intel annual meetings May). Portfolio-level trends: 6/10 high-materiality firms show YoY revenue growth averaging +65%, but margins mixed with gross improvements (FTC -0.9% vs -26.6%) amid covenant tightening; watch catalysts like WUTC rate approval Aug 1 and 10-K deadlines.

24 high priority 26 medium 50 total filings
· daily

Biotech Small-Cap Approvals — March 23, 2026

A cluster of five neutral FDA ANDA approvals for generic drugs (PALBOCICLIB, CLINDAMYCIN PHOSPHATE, DESOGESTREL, NINTEDANIB, CABOZANTINIB) occurred March 17-19, 2026, benefiting small-cap Asian sponsors (4/5 Indian/Chinese firms). All under standard review with no special designations or specified indications, signaling commoditized portfolio expansions rather than premium growth. Neutral implications dominate: modest operational wins offset by pricing pressures and limited visibility.

5 total filings
· daily

New Drug Approvals (Original) — March 23, 2026

FDA approved five neutral ANDA generics from March 17-19, 2026, all under standard review with no special designations or specified indications/therapeutic areas. Four approvals went to Indian sponsors (Natco, Aurobindo, Annora, Biocon) and one to China's Qilu, indicating routine portfolio expansions for emerging-market generic players. Three involve oncology drugs (PALBOCICLIB, NINTEDANIB, CABOZANTINIB), signaling modest competitive pressure in that sector without premium catalysts.

5 total filings
· daily

DHS Homeland Security Contracts — March 23, 2026

BCCG A Joint Venture secured three CBP delivery orders totaling $1.51B for border barrier construction in Weslaco, TX ($874M) and San Diego, CA ($639M combined), spanning 2025-2028 under full/open competition. This unprecedented concentration on one non-small JV signals strong DHS border security priorities and revenue backlog for NAICS 236220 contractors. Bullish for BCCG and sector peers, but $0 outlayed across awards flags near-term funding execution risks under firm-fixed pricing.

3 total filings
· daily

Federal Construction & Infrastructure Contracts — March 23, 2026

BCCG A Joint Venture dominates with $1.51B in CBP border wall contracts across TX and CA, fully obligated as base + options via full/open competition, signaling unmatched competitive edge in NAICS 236220. Multi-year performance (2.5-3 years to 2028) creates predictable revenue backlog for the JV. Zero outlays across all awards flag execution risks from funding delays or cost overruns under firm fixed price terms.

3 total filings
· daily

New Federal Contractors — March 23, 2026

BCCG A Joint Venture dominates with 3 DHS border barrier contracts totaling $1.51B (62% of period value), signaling strong federal priority on border infrastructure amid full/open competitions. HHS awards ($931M combined) highlight sustained demand for child services and medical staffing, though nonprofit status limits Family Endeavors equity appeal. $0 outlays on all BCCG contracts flag phased funding risks, prioritizing monitoring of execution starts in 2025.

5 total filings
· daily

Significant Contract Modifications ($10M+) — March 23, 2026

BCCG A Joint Venture dominates with $1.51B in DHS/CBP firm fixed price delivery orders for border wall systems in TX/CA (2025-2028), signaling strong revenue potential in NAICS 236220 construction amid policy-driven infrastructure. HHS contracts total $931M for child services ($714M obligated, 56% outlayed) and medical staffing ($217M obligated, 4% outlayed), offering neutral-to-bullish stability but execution risks from low disbursements. Concentration in border construction (62% of $2.44B total) warrants overweight in related equities, monitoring funding ramps.

5 total filings
· daily

Contract Deobligations Alert — March 23, 2026

BCCG A Joint Venture dominates with three DHS border wall contracts totaling $1.51B (62% of period value), signaling bullish momentum in border infrastructure construction amid full/open competitions. HHS awards to Family Endeavors ($714M, neutral nonprofit) and Spectrum Healthcare ($217M, bullish staffing) highlight services continuity but with execution risks from low outlays. Overall, $2.44B in obligations skewed to construction (NAICS 236220) offers revenue certainty through 2028 if funding materializes.

5 total filings
· daily

Contract Option Exercises — March 23, 2026

BCCG A Joint Venture dominates with three DHS border wall contracts totaling $1.51B (62% of stream value), signaling strong momentum in NAICS 236220 construction amid full/open competitions. HHS awards to Family Endeavors ($714M neutral nonprofit) and Spectrum Healthcare ($217M bullish) highlight services continuity but lower scale. Overall bullish stream with $2.44B obligated, though $0 outlay on border deals flags funding delays.

5 total filings
· daily

All HHS Contracts — March 23, 2026

HHS contracts total $931M, with 77% concentrated in a single neutral-rated nonprofit award to Family Endeavors for unaccompanied children services nearing 2025 expiration. Bullish signal from Spectrum Healthcare's $217M medical staffing deal with only 4% outlayed, signaling $208M potential disbursements despite 2022 end. Cross-cutting theme: low average outlay (32%) flags execution backlog but limited equity upside from nonprofit dominance.

2 total filings
· daily

Mega Contracts Monitor ($100M+) — March 23, 2026

BCCG A Joint Venture dominates with three DHS border wall contracts totaling $1.51B (62% of period value), signaling strong bullish momentum for border infrastructure construction amid full/open competition wins. Healthcare services awards to Spectrum ($217M, bullish) and Family Endeavors ($714M, neutral) highlight steady federal demand but lower equity upside due to nonprofit status and nearing end dates. Key risks include $0 outlays across BCCG awards and firm fixed-price structures, warranting monitoring for funding execution.

5 total filings
· daily

High-Value Federal Grants ($5M+) — March 23, 2026

BCCG A Joint Venture captures $1.51B across three DHS border wall contracts in TX and CA, representing 62% of the $2.44B total and signaling accelerated federal infrastructure spending under full open competition. HHS obligations totaling $931M focus on migrant child services and medical staffing, with partial outlays indicating phased execution. Bullish signals dominate (4/5), prioritizing construction firms in NAICS 236220 amid firm-fixed-price risks and zero early outlays on new awards.

5 total filings
· daily

General Federal Contracts — March 23, 2026

BCCG A Joint Venture dominates with $1.51B in three DHS border wall contracts (87%, 20%, 6% of total value), signaling accelerated federal border infrastructure spend through 2028 under full/open competition. HHS awards totaling $931M sustain child sheltering and medical staffing but carry neutral-to-bullish tones amid low outlays and nearing expirations. Overall $2.44B obligated (mostly $0 outlayed) prioritizes border construction (NAICS 236220) over services, warranting focus on BCCG execution amid firm-fixed-price risks.

5 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 23, 2026

Across 50 SEC filings dated March 23, 2026, in the USA S&P 500 Consumer Staples stream (with broader context), dominant themes include a surge in proxy statements (DEF 14A/DEFA14A for ~20 companies) preparing for May 2026 annual meetings, M&A and restructuring activity (e.g., CECO-Thermon merger with $40M synergies, RMBI-Farmers $82.4M deal, Honeywell Aerospace spin-off via $10B debt tender), and mixed FY25 financials where reported: revenue growth in outliers like CECO (+39% YoY to $774M, EBITDA +43% to $90M), US Antimony (+163% YoY to $39.3M), but declines in Aspen Aerogels (-40% YoY to $271.1M, $389.6M net loss) and Kimberly-Clark (-2.1% net sales to $16.4B despite +1.7% organic). Consumer Staples highlights show resilience via KMB's 54th consecutive dividend increase and $32B Kenvue acquisition (H2 2026 close), offset by Limoneira's dividend pause for capex. Period-over-period trends reveal volatility (avg reported rev change +300% skewed by small caps, but staples flat/declining), with positive capital allocation in dividends/buybacks absent specifics, and forward catalysts clustering in Q2 2026 (AGMs, mergers). Portfolio implications: Staples defensive amid macro but watch organic growth; alpha in M&A synergies and spin-offs.

31 high priority 19 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 23, 2026

Across 50 SEC filings from the USA S&P 500 Industrials stream (broadly encompassing aerospace, machinery, and adjacent sectors), key themes include robust M&A and spin-off activity (e.g., Honeywell Aerospace spin, Sealed Air acquisition), SPAC extensions/mergers, and mixed financial results with revenue growth in 7/15 reporting companies averaging +35% YoY (e.g., Arbutus +128%, SolarEdge +31%) offset by persistent losses and cash burn in biotechs/small caps. Period-over-period trends show margin improvements in 5 cases (e.g., Bionano gross margin to 46% from 1%, Cato FY SG&A to 35% from 36%), but declines in others (Core Labs op income -3.6% YoY, Cabaletta net loss +45%). Capital allocation leans toward buybacks/repurchases (Slide $125M, Guardian 1.8M shares) and debt refinancings (Hewlett Packard $2B notes, Waters $3.5B), signaling confidence amid high interest environments. Forward-looking catalysts cluster in 2H 2026 (Phase 3 trials, Nasdaq compliances), with positive regulatory clearances (Faraday SEC no-action) removing overhangs. Portfolio-level, industrials show relative strength in cap allocation vs. small-cap dilution risks, positioning sector for consolidation-driven alpha.

24 high priority 26 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — March 23, 2026

The five filings for the USA S&P 500 Energy intelligence stream feature routine proxy materials from non-energy firms (Halozyme Therapeutics in biotech, CommScope in telecom, and AParadise SPAC), highlighting a potential data mismatch but analyzed for governance insights; all exhibit neutral sentiment with materiality ranging 2-6/10 and no substantive financial or operational enriched data like YoY/QoQ trends, insider trading, capital allocation, or M&A details disclosed. Overarching themes include upcoming virtual annual meetings in early May 2026 for director elections, advisory compensation votes, and auditor ratifications, signaling standard proxy season kickoff without period-over-period financial comparisons or forward-looking guidance changes. No portfolio-level trends in revenue growth, margins, or ratios identifiable due to lack of metrics; SPAC PFIC statement provides minor positive ordinary earnings of $0.000605 per-share per-day for FY2025 with no capital gains/distributions. Critical developments center on scheduled AGMs as near-term catalysts for governance votes, with low proxy costs (e.g., CommScope $11k) indicating efficient shareholder engagement. Market implications are minimal for energy sector but offer tactical opportunities in voting participation and monitoring board stability across filings.

3 high priority 2 medium 5 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 23, 2026

Across 50 filings from the USA S&P 500 Financials stream (including banks, insurers, asset managers, and related services), dominant themes include elevated M&A activity (10+ filings on mergers like CECO/Thermon, Victory/Janus Henderson, Two Harbors bidding war), mixed 2025 financial performance with revenue growth in 7/15 10-Ks averaging +25% YoY (e.g., Finwise +31% assets, SUNation +26%) but declines in 8/15 averaging -20% (e.g., Aterian -30%, Ashford -6%), and proactive capital allocation via buybacks/dividends (Coeur $750M program, News Corp $1B authorization). Period-over-period trends show margin compression in 6/12 detailed cos (avg -150bps, e.g., Aterian gross margin 568bps drop) offset by strong growth in niche banking/insurance (Finwise NIM 9.23%, Progressive 12% premiums). Insider activity sparse but notable 10b5-1 plans (Avalo execs up to 471k shares) signal potential selling pressure; forward guidance largely raised (CECO +23% rev, Coeur gold prod +80%). Portfolio implications: overweight M&A targets/defenses (Two Harbors $10.75/share bid), monitor cyber/regulatory risks (Heritage incident, Volato delisting), with catalysts clustered Q2-H2 2026 (Phase trials, earnings). Overall bullish on capital returners, cautious on high-burn biotechs/hospitality.

31 high priority 19 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — March 23, 2026

Across 50 SEC filings from March 23, 2026, a dominant theme is robust corporate financing activity with 18 companies announcing new or amended credit facilities, debt refinancings, or equity offerings (e.g., $10M RenovoRx raise, $750M Ormat notes, $150M Unusual Machines offering), signaling improved liquidity and access to capital amid maturing prior debts. Leadership transitions dominate 22 filings, mostly orderly (e.g., promotions at Virtuix, retirements at Oil States), though some raise concerns like CEO departures at Mesa Labs and SiriusPoint. M&A and divestitures advanced positively (Coeur Mining acquisition boosting 2026 gold production 80% YoY to 680-815koz, Everest Group sale), alongside capital returns (Coeur $750M buyback + inaugural dividend). Period-over-period highlights include Sutro Biopharma's FY2025 revenue +65% YoY to $102.5M, net loss -16% to $191.1M, and RenovoRx's $900k revenue in 9M2025; however, cash burns persist in biotechs. Sector patterns show mining/energy strength (production guidance up, refinancings), financial/healthcare financing surge, but liquidity strains in smaller caps (MSP Recovery advances). Implications: Bullish for refinancings extending maturities (avg to 2029+), watch biotech catalysts, portfolio tilt to miners with buybacks.

50 high priority 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — March 23, 2026

Across these 10 filings from the S&P 500 Technology stream (including adjacent telecom, SPACs, and outliers like banking), dominant themes include active M&A/SPAC activity (3/10 filings) signaling consolidation, capital raise preparations via shelves and ATM offerings (3/10), and mixed FY2025/2026 financials with revenue growth but profitability challenges. Period-over-period trends show robust top-line growth in Planet Labs (+26% YoY revenue to $307.7M, Adj EBITDA to +$15.5M from -$10.6M) and Richmond Mutual (+23.4% net income to $11.6M, NIM to 2.97% from 2.67%), contrasted by asset quality deterioration (RMBI NPAs to 1.14% from 0.45%) and widened losses (PL net loss to $246.9M from $123.2M). Critical developments like TETE's SPAC merger proxy (low $142K trust signaling high redemptions) and RMBI's bank merger (38% ownership stake post-deal) imply dilution risks and arbitrage potential. Sector implications point to funding pressures amid growth investments, with Planet's deferred revenue surge (+165% to $248.1M) highlighting backlog strength. Portfolio-level, 2/3 detailed financials show margin stability/mixed (PL gross margin -100bps to 56%) but liquidity improvements (PL cash +94% to $229.4M).

5 high priority 5 medium 10 total filings